Is Wegovy the Same as Ozempic? Same Molecule, Different Medicines

The misconception worth clearing up first: same drug, completely different authorisations

The biggest source of confusion here is straightforward chemistry: Wegovy and Ozempic do share an active ingredient. Semaglutide is a GLP-1 receptor agonist that slows gastric emptying, reduces appetite signals and influences blood-sugar regulation. Because both brand names appear in the same news stories and both involve a once-weekly injection, many people assume they are interchangeable. They are not.

UK medicines licensing is specific to the product, not just the molecule. Ozempic holds a UK licence for adults with type 2 diabetes, at doses of 0.5mg, 1mg and 2mg weekly. Wegovy holds a separate UK licence for weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition, at doses up to 2.4mg weekly, and as of April 2026 a 7.2mg maintenance dose has also been approved by the MHRA, aimed at adults with obesity. For a deeper look at how semaglutide works across both products, our semaglutide overview covers the pharmacology in full.

A prescriber choosing Ozempic to manage someone's weight would be acting outside its licensed indication. That is not a technicality, it affects the evidence base the prescriber can draw on, the liability they carry, and the safety monitoring the medicine has been assessed for in that context. The MHRA has been explicit that GLP-1 medicines should not be used for quick or cosmetic weight loss, and that the right medicine for weight management is a licensed one.

How the doses tell the story

The dosing schedules for the two products illustrate just how different they are in practice. Ozempic typically starts at 0.25mg weekly as a tolerability period, moves to 0.5mg, then 1mg, with 2mg as the ceiling for diabetes management. Wegovy follows a different escalation: 0.25mg to 0.5mg to 1mg to 1.7mg to 2.4mg, reflecting the higher exposure needed to produce the appetite-related effects seen in the clinical trial programme. The STEP 1 trial, published in the New England Journal of Medicine, showed an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose, a result Ozempic's diabetes doses were never tested or authorised to achieve.

The approved 7.2mg Wegovy dose takes this further still, with trial data suggesting average weight loss approaching 20.7% over 72 weeks. That dose exists only within the Wegovy licence and is categorically not an Ozempic dose. The pens are also physically different: Ozempic and Wegovy are packaged, labelled and dispensed as distinct products, even at doses where the milligram figure might look similar on paper.

It is worth mentioning that questions about the two brands often spike at predictable moments, people tend to research this after seeing something in the news, or when they are first thinking about treatment. If you have been wondering whether Wegovy is simply the same thing as Ozempic, the answer is the same: the weight-loss product to ask about is Wegovy, not Ozempic.

What is actually licensed for weight loss in the UK?

Two injectable medicines hold UK marketing authorisations for weight management. Wegovy (semaglutide, Novo Nordisk) is one. Mounjaro (tirzepatide, Eli Lilly) is the other, a dual GIP and GLP-1 receptor agonist, which makes it the only medicine in its class currently licensed in the UK. Both require a prescription following a clinical assessment; neither can be purchased without one. For context on pricing and what a private prescription typically involves, our page on weight-loss treatment options covers that clearly.

Ozempic is not licensed for weight loss. Neither is Rybelsus, the oral semaglutide tablet approved for type 2 diabetes, a separate product entirely from the Wegovy tablet, which received MHRA approval in June 2026 as the UK's first oral GLP-1 medicine authorised for weight management. Attempting to source Ozempic for weight loss (particularly through social media or sellers not registered with the GPhC) carries real risks. The MHRA has repeatedly warned about counterfeit and unlicensed pens circulating online, some of which have contained insulin rather than semaglutide. A pharmacy on the GPhC register is the only safe place to source a prescription medicine. If you have come across compounded or peptide versions and wondered whether semaglutide peptide is the same as Ozempic, our page on that question goes into further detail, and our page on whether Ozempic and Wegovy are the same medicine covers how the two licensed brands compare as prescribable products.

Getting Wegovy through a regulated UK pharmacy

If Wegovy is the medicine a prescriber determines is right for you, the process at a regulated online pharmacy involves a clinical consultation, identity and weight verification, and a prescription issued by a qualified prescriber, not automated software. At nume, a GPhC-registered Independent Prescriber personally reviews every consultation. Our Wegovy treatment page explains the process, including what to expect at each stage, and our guide on where to buy Wegovy in the UK covers what to look for in a legitimate provider. You can also read more about the clinical team behind the service on our prescriber profile page.

If you are unsure whether Wegovy or Mounjaro is the more appropriate option for your circumstances, that is precisely the kind of question a prescriber should answer after a proper assessment, not something a webpage can resolve. Ready to take that step? Start your free consultation and have your case reviewed the same day.